Financings Roundup
• Trius Therapeutics Inc., of San Diego, said underwriters of its previously announced public offering exercised in full their option to purchase an additional 1.29 million shares to cover overallotments. Including the overallotment, the company grossed $51.9 million from the sale of 9.89 million shares priced at $5.25 apiece.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.